

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 19603/871 (CRF D-1792A)	SERIAL NO. 09/089,894
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)		APPLICANT Bomshteyn et al.	O I P E AUG 16 2000 PATENT & TRADEMARK OFFICE 1653
		FILING DATE June 3, 1998	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>Jal</i>	1	5,399,672	3/21/1995	Jalalian et al.	530	403	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPROPRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>Jal</i>		2	Rathnam et al., "Daunorubicin Conjugates of Antibodies to CA-125 and Lutropin Receptor," <u>FASEB Journal</u> , Experimental Biology 96, Washington, D.C. (April 14-17, 1996) (abstract)
<i>Jal</i>		3	Suwa et al., "Epidermal Growth Factor Receptor-Dependent Cytotoxic Effect of Anti-EGFR Antibody-Ribonuclease Conjugate on Human Cancer Cells," <u>Anticancer Research</u> 19:4161-4166 (1999)
<i>Jal</i>		4	Takahashi et al., "Experimental Treatment of Malignant Gliomas with Human Monoclonal Antibody-Drug Conjugates," <u>Anticancer Research</u> 19:4151-4156 (1999)
<i>Jal</i>		5	Charles et al., "Atrophy of Cholinergic Basal Forebrain Neurons Following Excitotoxic Cortical Lesions is Reversed by Intravenous Administration of an NGF Conjugate," <u>Brain Research</u> 728:193-203 (1996)
<i>Jal</i>		6	Roy et al., "Targeting T Cells Against Brain Tumors with a Bispecific Ligand-Antibody Conjugate," <u>Int. J. Cancer</u> 76:761-766 (1998)
<i>Jal</i>		7	Harapanhalli et al., "Lysine-Directed Conjugation of Ethidium Homodimer to B72.3 Antibody: Retention of Immunoreactivity but Altered Tumor Targeting," <u>Nuclear Medicine & Biology</u> 25:267-278 (1998)
<i>Jal</i>		8	Crosasso et al., "Antitumoral Activity of Liposomes and Immunoliposomes Containing 5-Fluorouridine Prodrugs," <u>Journal of Pharmaceutical Sciences</u> 86:832-839 (1997)
<i>Jal</i>		9	Cheng, "Bystander Killing of Tumour Cells by Antibody-Targeted Enzymatic Activation of a Glucuronide Prodrug," <u>British Journal of Cancer</u> 79:1378-1385 (1999)
<i>Jal</i>		10	Chang et al., "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature," <u>Cancer Research</u> 59:3192-3198 (1999)
<i>Jal</i>		11	Oosterwijk et al., "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," <u>Journal of Clinical Oncology</u> 11:738-750 (1993)
<i>Jal</i>		12	Texter et al., "The Role of Monoclonal Antibody in the Management of Prostate Adenocarcinoma," <u>The Journal of Urology</u> 160:2393-2395 (1998)
<i>Jal</i>		13	Kaminski et al., "Radioimmunotherapy of B-Cell Lymphoma With [¹³¹ I]Anti-B1 (Anti-CD20) Antibody," <u>The New England Journal of Medicine</u> 329:459-465 (1993)

EXAMINER

David L. Johnson

DATE CONSIDERED

11/27/00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6.9; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 19603/871 (CRF D-1792A)	SERIAL NO. 09/089,894
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary)		APPLICANT Bomshteyn et al.	 O I P E AUG 16 2000 1998 PATENT & TRADEMARK OFFICE
(PTO-1449)		FILING DATE June 3, 1998	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPROPRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6.9; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.